Clinical Trial Update: A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating safety and preliminary efficacy of [225Ac]Ac-DOTATATE in somatostatin receptor–positive gastroenteropancreatic neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Neoplasms

Drugs mentioned

• [225Ac]Ac-DOTATATE (Actinium-225 DOTATATE)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Neuroendocrine Neoplasm | Phase 1 | Status: RECRUITING